Total Clarity Wealth Management’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-22
Closed -$3K 557
2022
Q2
$3K Buy
+22
New +$2.61K ﹤0.01% 885
2022
Q1
Sell
-23
Closed -$4K 514
2021
Q4
$4K Hold
23
﹤0.01% 839
2021
Q3
$4K Buy
+23
New +$3.87K ﹤0.01% 844
2021
Q2
Sell
-22
Closed -$3K 417
2021
Q1
$3K Buy
+22
New +$3.49K ﹤0.01% 753
2020
Q1
Sell
-58
Closed -$7K 316
2019
Q4
$7K Buy
+58
New +$6.47K 0.01% 539

Other funds holding IBB

Total Clarity Wealth Management's IBB Position: Q3 2022 in Review

Total Clarity Wealth Management sold out of iShares Biotechnology ETF (IBB) in Q3 2022, closing a stake of 22 shares — an estimated $3K sold.

Total Clarity Wealth Management first reported a position in IBB in Q4 2019 and held it in 5 quarters. The position peaked at $7K in Q4 2019. 829 funds tracked by Wall St. Rank hold IBB as of Q3 2022.

  • Total Clarity Wealth Management reported no remaining iShares Biotechnology ETF position as of Q3 2022 after selling out during the quarter.
  • Total Clarity Wealth Management sold 22 iShares Biotechnology ETF shares in Q3 2022, an estimated $3K.
  • Total Clarity Wealth Management first reported a position in iShares Biotechnology ETF in Q4 2019 and held it in 5 quarters.
  • Total Clarity Wealth Management's iShares Biotechnology ETF position peaked at $7K in Q4 2019.
  • 829 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2022.

Based on Total Clarity Wealth Management's 13F filing for Q3 2022, filed 4 Nov 2022.